RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
Figure 2
Incidence of new vertebral fractures during study period in denosumab and placebo groups. Relative risk calculated for vertebral fracture in 679 patients in the denosumab group versus 673 patients in the placebo group were 0.15 (12 months), 0.31 (24 months), and 0.38 (36 months) [9].